Response to important orders received for MELISA(R) testing
MONTREAL, Dec. 6 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma is very
pleased to announce today the commercial launch of a new test for the
detection of titanium hypersensitivity during a mini symposium held in
Montreal on the effect of toxic metals and nanoparticles on human health.
Co-hosted by Biophage Pharma and the MELISA(R) Foundation, this Mini Symposium
was presented by Professor Vera Stejskal, inventor of the MELISA(R)
technology. Invited guests were given a tour of Biophage ImmunotoxLabs and
were able to interact with its scientists.
"More than 250 orthopedic surgeons, dentists and heath hygienists from
industries and laboratories working with metal alloys and nanoparticles were
invited to the mini symposium that was held at Biophage on December 4, 2007,"
commented Dr. Mandeville, President and CEO of Biophage Pharma. "We were
honored to have Professor Stejskal presenting the European experience with the
MELISA(R) technology. We also took this opportunity present our capabilities
and launch a new test to detect Titanium hypersensitivity. Increased demand
for titanium hypersensitivity testing lead us to add this new test to our list
that includes 10 metals used mainly in dental and orthopedic clinics. This new
test represents a growing source of revenues for Biophage, allowing us to
consolidate our product development activities (biosensor and phage therapy)
and their commercialization." added Dr. Mandeville.
The wide use of titanium oxide and titanium alloys in medicine, cosmetics
and skin care products means that an ever-increasing number of people are
exposed to this allergen. Moreover, occupational exposure to titanium dioxide
occurs frequently and the level of exposure may be high (aerospace industry,
the petroleum industry, electric power plants, the chemical industry, and the
automobile industry). In medicine, titanium is broadly used in orthopedic and
dental applications (dental implants, endoprotheses, stents, orthodontal
brackets, etc.). More recently, nanoparticles of titanium dioxide were used in
sunscreens because they are colorless at that size and still absorb
Recent studies have shown that titanium, or its corrosive by-products,
may cause inflammatory reactions in the blood, lungs, and bone marrow cells.
One particular form of this mineral that we should be concerned about is the
ultra-fine or nanoparticles as several studies have demonstrated that titanium
oxide toxicity was dependant on particle size and the smaller the size, the
more toxic it is. Faced with these potentially toxic effects on human health,
there is a real need for hypersentitivity testing, and the MELISA(R) is the
method of choice to respond to this need. For more information on
hypersensitivity testing please visit our website at (www.immunotoxlabs.com)
or contact us directly at 514-496-4508 or at email@example.com.
About Biophage Pharma Inc.
Biophage is a Canadian biotechnology company focused on the development
of innovative phage-based products and technologies for the detection,
prevention and control of bacterial infections. Biophage operates three
divisions: (1) The Immunotox Labs division, which provides services in
Immunogenicity and Immunotoxicity, screening for Beryllium sensitization (the
BeLPT test) and exclusive MELISA(R) for the detection of sensitization to more
than 200 different allergens including metals, penicillin, gluten, pollens and
more recently Lyme disease (Boreliosis); (2) The Biosensors division for the
development and commercialization of Biosensors PDS(R); and (3) The
Therapeutics division for the prevention and control of bacterial
contaminations in the medical, veterinary and environment fields. Both the
Biosensor and Phage therapy programs have been structured to deliver an
environmentally safe solution for the early detection and rapid control of
deadly microorganisms. (www.biophagepharma.net; www.immunotoxlabs.com)
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Rosemonde Mandeville, M.B., Ch.B., PhD.,
President and CEO, Biophage Pharma Inc., (514) 496-1488,
firstname.lastname@example.org; Miguel Retamal, M.Sc., Director,
ImmunotoxLabs, (514) 496-4508, email@example.com